NexturnBioscience Co. Ltd (089140) — Financial Flexibility Index
NexturnBioscience Co. Ltd (089140) has a Financial Flexibility Index of 0.04x as of September 2025. Free cash flow of ₩4.80 Billion (operating CF ₩4.51 Billion minus capex ₩286.65 Million) represents 0% of total liabilities (₩128.65 Billion). Check 089140 cash reinvestment to operating cash ratio to assess the company's total reinvestment commitment from operating cash flow.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
NexturnBioscience Co. Ltd Financial Flexibility Index (2014–2024)
Historical Financial Flexibility Index trend for NexturnBioscience Co. Ltd across 11 annual periods. For the full cash flow conversion analysis, see NexturnBioscience Co. Ltd cash flow conversion.
Annual Financial Flexibility Index for NexturnBioscience Co. Ltd (2014–2024)
Year-by-year free cash flow to debt coverage for NexturnBioscience Co. Ltd. Explore 089140 cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.
| Year | Flexibility Index | Free Cash Flow (KRW) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2024 | 0.00x | ₩-412.57 Million | ₩-1.14 Billion | ₩96.41 Billion | ▲ +48.9% |
| 2023 | -0.01x | ₩-888.34 Million | ₩-1.97 Billion | ₩105.98 Billion | ▲ +15.1% |
| 2022 | -0.01x | ₩-908.42 Million | ₩-1.19 Billion | ₩91.98 Billion | ▼ -111.0% |
| 2021 | 0.09x | ₩4.13 Billion | ₩3.66 Billion | ₩46.21 Billion | ▼ -84.1% |
| 2020 | 0.56x | ₩1.45 Billion | ₩235.94 Million | ₩2.58 Billion | ▼ -86.7% |
| 2019 | 4.21x | ₩21.12 Billion | ₩2.74 Billion | ₩5.01 Billion | ▲ +672.4% |
| 2018 | 0.55x | ₩9.83 Billion | ₩9.63 Billion | ₩18.01 Billion | ▼ -72.6% |
| 2017 | 1.99x | ₩5.95 Billion | ₩5.08 Billion | ₩2.99 Billion | ▼ -8.3% |
| 2016 | 2.17x | ₩18.77 Billion | ₩17.88 Billion | ₩8.64 Billion | ▲ +143.8% |
| 2015 | 0.89x | ₩2.82 Billion | ₩1.92 Billion | ₩3.17 Billion | ▼ -39.5% |
| 2014 | 1.47x | ₩6.49 Billion | ₩6.48 Billion | ₩4.41 Billion | — |